| Followers | 35 |
| Posts | 1912 |
| Boards Moderated | 0 |
| Alias Born | 11/05/2020 |
Saturday, April 30, 2022 10:37:24 AM
Common sense shows that Koos can't find anyone other than his brother, who is far from qualified to do what he is paid an over inflated price to do!
Let's take this a step further....
Even more common sense is the fact that Koos paid his brother $117,000 (this could be a yearly salary) for research when he could have used those funds to hire a CSO.
Even Thomas Ichim could have been rehired for that amount of money as a "consultant CSO" and done this "research" job.
If Koos owed Ichim in any way, shape or form, wouldn't you think he would payback or at least attempt too?
We know that Ichim re-posted a tweet from Koos about his work on NR2F6. So it's not like Koos couldn't extend a hand here.
Yet, he hires his brother for an insane amount of money to figure out what NR2F6 could do and then find the right people to work with it? This was already done "supposedly" with Biotech Research Group. Somewhere there are red alarms going off!
It's a circus that lost it's ring leader.
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
